Physician profile
Jennifer A Marrone
NPI 1568629384
$4,460.47
in general payments reported to CMS, 2019-2025
25 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 93% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $153 · 2021: $382 · 2022: $687 · 2023: $852 · 2024: $826 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.04 |
| Education | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $1,611.79 | 2022-2025 | Slynd |
| Abbvie INC. | $550.44 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $470.64 | 2022-2025 | |
| Pfizer INC. | $269.88 | 2020-2024 | |
| Astellas Pharma US INC | $265.93 | 2024-2025 | Veozah |
| Millicent US INC | $239.98 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Therapeuticsmd, INC. | $190.43 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.97 | 2020-2025 | |
| Exact Sciences Corporation | $129.31 | 2023-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $104.28 | 2020-2022 | |
| Shield Therapeutics INC | $75.45 | 2024-2025 | |
| Aspira Women'S Health INC | $73.61 | 2024-2025 | Ova1 |
| Avion Pharmaceuticals | $67.42 | 2021 | |
| Agile Therapeutics, INC. | $39.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.85 | 2020-2024 | Gardasil 9, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $31.26 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Ascend Therapeutics US, LLC | $25.88 | 2022 | |
| Roche Diagnostics Corporation | $25.05 | 2019 | |
| Lupin INC. | $20.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.25 | 2024 | Xifaxan |
| Biogen, INC. | $18.77 | 2025 | Zurzuvae |
| Organon LLC | $18.35 | 2022 | |
| Duchesnay USA Incorporated | $12.76 | 2019 | |
| Hologic Sales and Service, LLC | $11.47 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Marrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.